Biotech Values

[DewDiligence]

ANA380 R.I.P.

From today’s ANDS PR:
http://biz.yahoo.com/prnews/070503/lath109b.html?.v=1

>>
“We continued discussions with LG Life Sciences around a global development plan for ANA380, a nucleotide inhibitor of HBV polymerase; however, to date, the parties have not been able to come to agreement on a global development plan that would support the interests of both parties' respective geographic territories. Accordingly, we are currently re-evaluating the role of ANA380 in our product portfolio and are evaluating our options with respect to this program.”
<<

ANA380 (not to be confused with ANA975) is the drug candidate for HBV that NVS opted not to license despite having the exclusive option to do so.